Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage

被引:9
作者
Siris, Ethel S. [1 ]
Yu, Jingbo [2 ]
Bognar, Katalin [3 ]
DeKoven, Mitch [4 ]
Shrestha, Anshu [3 ]
Romley, John A. [5 ]
Modi, Ankita [2 ]
机构
[1] Columbia Univ, Med Ctr, NY Presbyterian Hosp, Toni Stabile Osteoporosis Ctr, New York, NY USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Precis Hlth Econ, Los Angeles, CA USA
[4] IMS Hlth, Real World Evidence Solut, Fairfax, VA USA
[5] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA
关键词
gastrointestinal; osteoporosis; postmenopausal women; treatment initiation; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; TRAUMA FRACTURES; HIP-FRACTURES; COHORT; HOSPITALIZATION; ASSOCIATION; POPULATION; PREDICTORS; MANAGEMENT;
D O I
10.2147/CIA.S83488
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Objectives: To examine the rate of osteoporosis (OP) undertreatment and the association between gastrointestinal (GI) events and OP treatment initiation among elderly osteoporotic women with Medicare Part D drug coverage. Methods: This retrospective cohort study utilized a 20% random sample of Medicare beneficiaries. Included were women >66 years old with Medicare Part D drug coverage, newly diagnosed with OP in 2007-2008 (first diagnosis date as the index date), and with no prior OP treatment. GI event was defined as a diagnosis or procedure for a GI condition between OP diagnosis and treatment initiation or at the end of a 12-month follow-up, whichever occurred first. OP treatment initiation was defined as the use of any bisphosphonate (BIS) or non-BIS within 1 year postindex. Logistic regression, adjusted for patient characteristics, was used to model the association between 1) GI events and OP treatment initiation (treated versus nontreated); and 2) GI events and type of initial therapy (BIS versus non-BIS) among treated patients only. Results: A total of 126,188 women met the inclusion criteria: 72.1% did not receive OP medication within 1 year of diagnosis and 27.9% had GI events. Patients with a GI event were 75.7% less likely to start OP treatment (odds ratio [OR]=0.243; P<0.001); among treated patients, patients with a GI event had 11.3% lower odds of starting with BIS versus non-BIS (OR=0.887; P<0.001). Conclusion: Among elderly women newly diagnosed with OP, only 28% initiated OP treatment. GI events were associated with a higher likelihood of not being treated and, among treated patients, a lower likelihood of being treated with BIS versus non-BIS.
引用
收藏
页码:1813 / 1824
页数:12
相关论文
共 37 条
[1]
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture [J].
Andrade, SE ;
Majumdar, SR ;
Chan, KA ;
Buist, DSM ;
Go, AS ;
Goodman, M ;
Smith, DH ;
Platt, R ;
Gurwitz, JH .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (17) :2052-2057
[2]
[Anonymous], 2014, CLIN GUID PREV TREAT
[3]
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA [J].
Asche, C. ;
Nelson, R. ;
McAdam-Marx, C. ;
Jhaveri, M. ;
Ye, X. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (08) :1427-1436
[4]
Patient and physician predictors of post-fracture osteoporosis management [J].
Block, Adam E. ;
Solomon, Daniel H. ;
Cadarette, Suzanne M. ;
Mogun, Helen ;
Choudhry, Niteesh K. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (09) :1447-1451
[5]
Medical costs of osteoporosis in the elderly Medicare population [J].
Blume, S. W. ;
Curtis, J. R. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (06) :1835-1844
[6]
Factors predicting osteoporosis treatment initiation in a regionally based cohort [J].
Cranney, A. ;
Tsang, J. F. ;
Leslie, W. D. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (09) :1621-1625
[7]
Daniels Alan H, 2014, Am J Orthop (Belle Mead NJ), V43, pE146
[8]
The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008 [J].
Dawson-Hughes, B. ;
Looker, A. C. ;
Tosteson, A. N. A. ;
Johansson, H. ;
Kanis, J. A. ;
Melton, L. J., III .
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (03) :811-820
[9]
Updated fracture incidence rates for the US version of FRAXA® [J].
Ettinger, B. ;
Black, D. M. ;
Dawson-Hughes, B. ;
Pressman, A. R. ;
Melton, L. J., III .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (01) :25-33
[10]
Ettinger B., 1998, J Managed Care Pharm, V4, P488, DOI [10.18553/jmcp.1998.4.5.488, DOI 10.18553/JMCP.1998.4.5.488]